Incyte, a US-based biotechnology firm, has announced the results of a Phase 3 clinical trial for its experimental lymphoma treatment, iberdomide. The trial, which involved 433 patients with relapsed or refractory multiple myeloma, showed that the drug significantly improved patient outcomes, including a reduction in disease progression and an increase in overall survival rates.
The trial results, which were presented at the American Society of Haematology Annual Meeting, demonstrated that iberdomide achieved a statistically significant improvement in progression-free survival (PFS) and overall survival (OS) compared to a placebo. The trial also showed that the drug was well-tolerated, with a safety profile consistent with previous studies.
Incyte's Chief Medical Officer, Steven Hooper, stated that the trial results are a significant step forward for patients suffering from lymphoma, and that the company is committed to bringing this promising treatment to patients as quickly as possible. The company plans to submit a New Drug Application (NDA) to the US Food and Drug Administration (FDA) in the second half of 2024.
Analysts have welcomed the trial results, highlighting the potential for iberdomide to become a new standard of care for patients with relapsed or refractory multiple myeloma. The results also underscore the growing importance of immunomodulatory therapies in the treatment of cancer.
Shares in Incyte rose 3.5% on the news, with investors betting on the potential for the company to secure regulatory approval for iberdomide in the near future. The news has also boosted the outlook for the biotechnology sector, with analysts predicting a strong year ahead for the industry.